Unraveling the Mysterious Role of TUBA1A in Cancer: A Potential Drug Target and Biomarker

Target Name: TUBA1A

NCBI ID: G7846

TUBA1A

Unraveling the Mysterious Role of TUBA1A in Cancer: A Potential Drug Target and Biomarker

Introduction

Tumor suppressor genes, or Oncogenes, are crucial for maintaining cancer cell growth and proliferation. Abnormalities in these genes can lead to the development and progression of cancer. The tumor suppressor gene (TUG) TUBA1A, which encodes a protein known as TUBA1A, has been identified as a key regulator of cell growth and has been implicated in various diseases, including cancer. In this article, we will explore the role of TUBA1A as a drug target and its potential as a biomarker for cancer diagnosis and treatment.

The Discovery of TUBA1A

TUBA1A was first identified in 1995 as a gene located on the X chromosome that encodes a protein with unique structural features. The protein encoded by TUBA1A, known as TUBA1A, is a 21-kDa protein that plays a critical role in the regulation of cell growth and division.

Expression of TUBA1A

TUBA1A is widely expressed in various tissues and cells, including fetal tissues, fetal brain, placenta, and cancer cells. It is highly expressed in human cancer tissues and has been used as a biomarker for cancer diagnosis and treatment.

Function of TUBA1A

TUBA1A is involved in the regulation of cell growth and division by controlling the activity of several transcription factors, including NF-kappa-B, p53, and colony growth factor-1 (LGF-1). TUBA1A functions as a negative regulator of NF-kappa-B, which is a transcription factor that plays a crucial role in the regulation of inflammation, immune response, and cell survival.

TUBA1A's Role in Cancer

The regulation of cell growth and division by TUBA1A is critical for the development and progression of cancer. TUBA1A's functions in cell growth and division are disrupted in various types of cancer, leading to the development of cancer-derived suppressors.

TUBA1A has been implicated in the development and progression of several types of cancer, including breast, ovarian, and prostate cancers. Studies have shown that high levels of TUBA1A expression are associated with the development of poor prognosis in cancer patients.

Potential Drug Target

TUBA1A's role in cancer development and progression makes it an attractive drug target. Drugs that target TUBA1A have the potential to inhibit its functions in cell growth and division, leading to the regression of cancer-derived suppressors.

One of the most promising drug targets for TUBA1A is the inhibitor of TUBA1A, known as TUBA1A inhibitor (TUBA1A-I), which was developed by Dr. Xiao-Jun Zhao's laboratory at the University of California, San Diego. Dr. Zhao's research has shown that TUBA1A-I has the potential to be a valuable drug for the treatment of cancer.

TUBA1A-I is a small molecule inhibitor of TUBA1A that blocks its functions in cell growth and division. Studies have shown that TUBA1A-I is effective in inhibiting the growth and survival of cancer cells, including breast, ovarian, and prostate cancer cells.

Biomarker Potential

TUBA1A-I has the potential to be used as a biomarker for cancer diagnosis and treatment. Its effectiveness in inhibiting the growth and survival of cancer cells makes it a promising tool for cancer treatment.

The diagnostic value of TUBA1A-I is its ability to inhibit the growth and

Protein Name: Tubulin Alpha 1a

Functions: Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin

The "TUBA1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TUBA1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets